

VOLUMEN XLVIII

NUMERUS suppl 1

LIBRI ONCOLOGICI

CROATIAN JOURNAL OF ONCOLOGY

Zagreb, 2020

CROATIAN JOURNAL OF ONCOLOGY
LIBRI ONCOLOGICI

Publisher

Sestre milosrdnice University Hospital Center
University Hospital for Tumors, Zagreb, Croatia

Editor-in-Chief

Danko Velimir Vrdoljak

Editors

Lidija Beketić-Orešković, Zvonko Kusić, Božena Šarčević

Associate Editors

Iva Kirac – Experimental Research
Mladen Stanec – Surgical Oncology
Robert Šeparović – Medical Oncology
Hrvoje Šobat – Radiation Oncology

Technical Editor

Anica Vrdoljak

Editorial Board

Gordana Brozović, Željko Herceg, Ljiljana Mayer, Ivan Milas, Aleksandar Milenović, Marija Pastorčić-Grgić, Mario Puljiz, Vesna Ramljak, Andrej Roth, Sanda Šitić, Tiha Vučemilo.

Editorial Council

D. Babić (Zagreb, Croatia), V. Banović (Zagreb, Croatia), A. Bolanča (Zagreb, Croatia), M. Ćorić (Zagreb, Croatia), T. Čufer (Ljubljana, Slovenia), N. Đaković (Zagreb, Croatia), D. Eljuga (Zagreb, Croatia), G. Fisher (Stanford, USA), M. Gamulin (Zagreb, Croatia), H. Haller (Rijeka, Croatia), J. Jassem (Gdansk, Poland), A. Juretić (Zagreb, Croatia), A. Karamarković (Belgrade, Serbia), D. Kalafatić (Zagreb, Croatia), S. Kaštelan (Zagreb, Croatia), Ž. Kaštelan (Zagreb, Croatia), M. Klarica (Zagreb, Croatia), A. Lancia (Pavia, Italy), S. Levanat (Zagreb, Croatia), D. Marčinko (Zagreb, Croatia), S. Orešković (Zagreb, Croatia), P. Ozretić (Zagreb, Croatia), S.Ž. Pavletić (Bethesda, USA), R. Pirker (Wien, Austria), K. Rotim (Zagreb, Croatia), M. Solaric (Zagreb, Croatia), B.I. Šikić (Stanford, USA), I. Tomaš (Osijek, Croatia), D. Vrbanec (Zagreb, Croatia), E. Vrdoljak (Split, Croatia), Ž. Vujašković (Baltimore, USA), M. Zovak (Zagreb, Croatia).

Indexed in SCOPUS and EMBASE/Excerpta Medica

Editorial Office:

LIBRI ONCOLOGICI, Ilica 197, 10 000 Zagreb, Croatia, P.O. Box 427,

Phone (385 1) 37 83 522, Fax (385 1) 37 75 536

Web site: <http://hrcak.srce.hr/libri-oncologici>

e-mail: libri.oncologici@kbcsm.hr

The journal is published three times a year. Orders can be placed directly to the Editorial Office.

Price per copy 60 HRK. Annual subscription rates in Croatia: 300 HRK + VAT for institutions, 150 HRK + VAT for individuals and 60 HRK + VAT for students, to be remitted with Hrvatska narodna banka, account HR12 1001 0051 8630 0016 0 Ref.No.HR65 7129-051-26395 (for LIBRI ONCOLOGICI).

Annual subscription abroad - equivalent of US\$ 50 to be paid into the foreign currency account with Hrvatska narodna banka, IBAN: HR12 1001 0051 8630 0016 0 (Ref.No.HR65 7129-051-26395), BIC code: NBHRHR2XXXX (for LIBRI ONCOLOGICI)

Cover Design: Osman Berberović

Typesetting and printed by DENONA d.o.o., Zagreb



13 HRVATSKI ONKOLOŠKI KONGRES 13th CROATIAN ONCOLOGY CONGRESS

03-06.09.2020, Center Gervais
Opatija, Croatia

Supplement editors:
Eduard Vrdoljak and Marijana Jazvić

Zagreb, Croatia
September, 2020

ORGANIZER

Hrvatsko onkološko društvo - Hrvatski liječnički zbor
Croatian society of Oncology

Chair of the organizing committee

prof. dr. sc. Eduard Vrdoljak, dr. med.

Organizing committee:

Ante Bolanča
Lidija Beketić Orešković
Tanja Čufer
Višnja Matković
Miroslav Samaržija
Mladen Solarić
Stipislav Jadrijević
Nina Dabelić
Marijo Boban
Marko Zelić
Snježana Tomić
Ante Ćorušić

Scientific committee:

Tanja Badovinac-Črnjević
Goran Golčić
Davor Štimac
Herman Haller
Marko Jakopović
Tomislav Omrčen
Josip Paladino
Boris Ružić
Sven Seiwerth
Hrvoje Šobat
Dag Zahirović
Ariana Znaor
Liana Cambj Sapunar
Mario Šekerija
Željko Soldić
Tihana Boraska Jelavić
Josipa Flam
Boris Brkljačić
Igor Aurer
Martina Bašić Koretić

Sponsors and exhibitors:

ABBOTT
ABBVIE
ALVOGEN
AMGEN
ASTELLAS
ASTRAZENECA
BAYER
BELUPO
BOEHRINGER INGELHEIM
BRISTOL-MYERS SQUIBB
CELGENE
ELI LILLY
FARMEX
"JANSSEN: PHARMACEUTICAL COMPANIES
OF JOHNSON&JOHNSON"
LABENA
MEDIATELY

MERCK
MSD
MYLAN HRVATSKA
NOVARTIS
OKTAL PHARMA
PFIZER
PHARMASWISS
PLIVA HRVATSKA
ROCHE
SALVUS
SANDOZ
SANOFI GENZYME
SEQUENTIA
SERVIER
SYNLAB
VELMED

CONTENTS

ORAL PRESENTATIONS

BREAST CANCER	3
Snježana Tomić	
S1 - Role of pathologist in modern oncological treatment	3
Paula Podolski, Nera Šarić	
S2 - The current approach in neoadjuvant systemic treatment of breast cancer patients .	5
Tajana Silovski	
S3 - Adjuvant therapy for breast cancer today	7
Marija Ban	
S4 - Optimal treatment of advanced luminal breast cancer	9
Martina Bašić Koretić, Majana Soče, Maja Baučić, Marko Bebek, Sanja Šandrk, Ivan Zrilić, Sanja Brnić	
S5 - Optimal treatment options of metastatic HER2 positive breast cancer	11
Natalija Dedić Plavetić	
S6 - The optimal treatment of metastatic triple negative breast cancer	15
Inga Marijanović, Marija Kraljević, Krešimir Tomić, Eduard Vrdoljak	
S7 - A case report of luminal breast cancer	17
SUPPORTIVE THERAPY	18
Ivan Radoš, Damir Gugić	
S8 - Management of cancer pain	18
LUNG CANCER	20
Marijo Boban	
S9 - Optimal treatment of stage III non-small cell lung cancer	20
Marko Jakopović, Fran Seiwerth, Lela Bitar, Miroslav Samaržija	
S10 - Treatment of EGFR mutated NSCLC	22

Krešimir Tomić	
S11 - Case presentation: ALK-positive metastatic lung cancer	24
Vide Popović	
S12 - Metastatic lung cancer treated with immunotherapy	25
GASTROINTESTINAL TUMORS	26
Josipa Flam, Damir Gugić, Suzana Erić, Mirela Šambić-Penc, Ilijan Tomaš, Ivana Canjko	
S13 - Optimal treatment of locoregional rectal cancer	26
Tomislav Omrčen	
S14 - Immunotherapy in treatment of gastrointestinal tumors	28
Borislav Belev	
S15 - Gastrointestinal neuroendocrine tumors	32
Jasna Radić, Jasmina Marić Brozić, Željko Soldić, Ana Fröbe	
S16 - Novel treatment options for hepatocellular carcinoma and biliary tract carcinoma	34
Vesna Bišof	
S17 - Neoadjuvant / adjuvant treatment of gastric cancer	36
GYNECOLOGICAL TUMORS	38
Jasna Marušić, Ani Mihaljević Ferari, Ingrid Belac Lovasić	
S18 - Updates on cervical cancer treatment	38
Kristina Katić, Višnja Matković	
S19 - Optimal treatment of endometrial cancer	41
Ivana Tica Sedlar, Branka Petrić Miše	
S20 - Metastatic recurrent endometrial cancer: a case report	44
MELANOMA	45
Nina Dabelić, Jasmina Marić Brozić, Ana Fröbe	
S21 - Recent advances in targeted therapies of melanoma	45
Antonio Juretić	
S22 - Cutaneous melanoma immunotherapy	48
Jasmina Marić Brozić, Nina Dabelić, Nikola Đaković, Ana Fröbe	
S23 - Immunotherapy side effects and how to treat them	50
Ana Majić, Branka Petrić - Miše, Eduard Vrdoljak	
S24 - BRAF mutant metastatic melanoma: a case report	53
Uroš Smrdel	
S25 - Stereotaxy	54

UROGENITAL TUMORS	56
Marija Gamulin	
S26 - Testicular cancer – between de-escalation and high-dose chemotherapy with peripheral blood stem-cell transplantation	56
Dag Zahirović	
S27 - Hormonal therapy of prostate cancer	58
Milena Gnjudić	
S28 - Prostate cancer: what's new in non-hormonal systemic treatment	60
Mladen Solarić	
S29 - News in prostate cancer radiotherapy	61
Tihana Boraska Jelavić	
S30 - Neoadjuvant and adjuvant treatment of bladder cancer	63
Marijana Jazvić, Jure Murgić, Marija Miletić, Ana Fröbe	
S31 - New developments in treatment of metastatic bladder cancer	65
Jure Murgić, Marijana Jazvić, Marija Miletić, Ana Fröbe	
S32 - New developments and update on treatment of metastatic kidney cancer	67
Zvonimir Curić	
S33 - Renal cell carcinoma – case report	69

POSTER PRESENTATIONS

Tomislav Pavlović, Sanja Trtica, Rosana Troškot Perić	
P1 - Melena caused by gastric lipoma	73
Davor Kust, Jure Murgić, Petra Vuković, Ivan Kruljac, Marin Prpić, Ana Žilić, Csongor Lengyel, Kamil Wdowiak, Lina Simaskaite, Uluk Mutlu Gunaydin, Ivana Tica Sedlar, Elena Fountzilias, Urška Janžič, Iulia Coroian, Ivana Durutović, Benedetta Pellegrino, Mila Petrova, Emiljana Huti, Elena Napolskaia, Boštjan Šeruga, Antonija Balenović, Ana Fröbe, Krešimir Luetić	
P2 - Multinational survey of Burnout syndrome in Eastern European oncologists . . .	75
Marin Šunjić, Jasna Radić, Željko Soldić, Jasmina Marić Brozić, Davor Kust, Ana Fröbe	
P3 - Response to neoadjuvant chemoradiotherapy for rectal adenocarcinoma: a single center experience	77
Marija Miletić, Marijana Jazvić, Jure Murgić, Angela Prgomet Sečan, Ana Fröbe	
P4 - Impact of first-line tyrosine kinase inhibitors dose reduction on clinical outcomes in patients with metastatic kidney cancer: a single institution experience	78
Marin Šunjić, Kristina Urch, Jasmina Marić Brozić, Nina Dabelić, Jure Murgić, Ana Fröbe	
P5 - Treatment outcomes of targeted therapy with BRAF and MEK inhibitors in patients with metastatic melanoma at Sestre milosrdnice University Hospital Center, Zagreb	80

Gordana Berić Jozić, Ivana Tica Sedlar, Krešimir Tomić, Inga Marijanović P6 - Mucositis during the treatment of head and neck cancer patients with radiotherapy +/- chemotherapy – real clinical practice experience	82
Krešimir Tomić, Inga Marijanović, Maja Pezer Naletilić, Dragana Miletić, Gordana Berić Jozić, Eduard Vrdoljak P7 - Nivolumab immunotherapy as a part of the expanded access programs for the treatment of patients with lung carcinoma	83
Krešimir Tomić, Ana Parić, Gordana Berić Jozić, Sanda Čale, Inga Marijanović P8 - Local control of locally advanced cervical cancer in patients treated with primary concomitant chemobrachyradiotherapy in Department of oncology, University Hospital Mostar	84
Inga Marijanović, Marija Kraljević, Teo Buhovac, Dragana Karan Križanac P9 - A rare her-2 positive neuroendocrine carcinoma of the breast: a 9-year follow-up case report	85
Manda Švabić Kolacio, David Rajlić, Đeni Smilović Radojčić, Nevena Obajdin, Ingrid Belac Lovasić, Slaven Jurković P10 - Analysis of the application of different clinical CT imaging protocols as factors in the calculation of absorbed dose distributions using the elekta monaco radiotherapy planning system	87
Nevena Obajdin, Đeni Smilović Radojčić, Dag Zahirović, Manda Švabić Kolacio, David Rajlić, Ingrid Belac-Lovasić, Slaven Jurković P11 - Comparison of two planning techniques (F-IMRT/I-IMRT) for post-operative radiotherapy treatment of prostate cancer	89
Andrija Katić, Dora Čerina, Ana Paparella Karaman, Darijo Hrepić, Eduard Vrdoljak P12 - Can optimally organized cancer care have an impact on the transition of patients with metastatic colorectal cancer through treatment lines? - a retrospective observational study at the Department of Oncology and Radiotherapy, University Hospital of Split	91
Andrija Katić, Dora Čerina, Ana Paparella Karaman, Darijo Hrepić, Eduard Vrdoljak P13 - Treatment outcomes by primary tumor location in patients with metastatic colorectal cancer at the Department of Oncology and Radiotherapy, University Hospital of Split during 2017 - a retrospective analysis.	93
Andrija Katić, Dora Čerina, Ana Paparella Karaman, Darijo Hrepić, Eduard Vrdoljak P14 - The impact of liver resection on treatment outcomes of metastatic colorectal cancer patients at the Department of Oncology and Radiotherapy, University Hospital of Split during 2017 - a retrospective analysis	95
Marija Pancirov, Bisera Mamić, Ana Paparella Karaman, Eduard Vrdoljak P15 - Experiences with neoadjuvant therapy for breast cancer in our clinic in 2018 . . .	97

Lela Bitar, Fran Seiwerth, Ana Bačelić-Gabelica, Dražen Srđić, Marta Koršić, Sanja Pleština, Suzana Kukulj, Miroslav Samaržija, Marko Jakopović P16 - Immune checkpoint inhibitors combined with chemotherapy in extensive-stage small-cell lung cancer – single center experience	98
Ana Majić, Ivan Urlić, Marija Pancirov, Ana Paparella - Karaman, Ante Strikić, Marija Ban, Darijo Hrepić, Eduard Vrdoljak P17 - Hematologic toxicity of cyclin dependent kinase 4/6 (CDK4/6) inhibitors palbociclib and ribociclib during first three cycles of 1st line treatment of metastatic breast cancer - retrospective analysis in single centre	99
Viktor Šabarić, Kristina Kanceljak, Nikolina Lonjak, Tamara Žigman, Ivana Rako, Kristina Gotovac Jerčić, Fran Borovečki, Tajana Silovski, Natalija Dedić Plavetić P18 - The role of genetic testing in breast cancer patients undergoing neoadjuvant treatment	100
Nikolina Lonjak, Kristina Kanceljak, Viktor Šabarić, Tajana Silovski, Natalija Dedić Plavetić, Tamara Žigman, Ivana Rako, Kristina Gotovac Jerčić, Fran Borovečki P19 - Non-brca germline pathogenic variants in breast cancer patients tested at the University Hospital Center Zagreb	102
Kristina Kanceljak, Viktor Šabarić, Nikolina Lonjak, Tamara Žigman, Ivana Rako, Kristina Gotovac Jerčić, Fran Borovečki, Tajana Silovski, Natalija Dedić Plavetić P20 - Genetic assessment and treatment decision-making in patients with metastatic breast cancer in University Hospital Center Zagreb	104
Petra Radić, Marta Ritoša, Marina Alaber, Ljuba Doko, Carla Ćorić, Ivana Marić, Borna Trogrlić, Berislav Tkalčević, Ljiljana Vukota, Dea Ajduković P21 - Making of a clinically useful questionnaire for assessment of emotional distress in patients with cancer	106
Snježana Ramić, Melita Perić Balja, Velda Smajlbegović, Marija Marušić, Tomislav Orešić, Ivan Milas P22 - Pretreatment KI67 and the efficacy of neoadjuvant chemotherapy in breast cancer	107
Petra Lepetić, Dejana Jezernik, Kristina Kanceljak, Ana Tečić Vuger, Marijana Pavlović, Ljubica Vazdar, Robert Šeparović P23 - Assessment of creatinine level rise in cancer patients treated with ribociclib and antihormonal therapy at the University Hospital for Tumors	109
Rosana Troskot Perić, Danijel Bevanda, Luči Goleš, Dubravka Jandrić, Gabrijela Stanić, Dragan Jurčić, Filip Bedenik, Nikolina Tolj, Tomislav Pavlović, Sanja Trtica P24 - How to distinguish primary from acquired achalasia?: a patient with achalasia and cancer of both kidneys	110

Kristina Katić, Višnja Matković, Ante Ćorušić P25 - Tolerability of bevacizumab in elderly patients with ovarian cancer: an experience from the Department of Gynecologic Oncology in the University Hospital Centre Zagreb	112
Ivan Viculin, Jelena Viculin, Marijo Boban, Lidija Bošković, Eduard Vrdoljak, Tihana Boraska Jelavić P26 - The efficacy and safety of concurrent chemoradiotherapy in patients with non-small cell lung cancer - single institution study at Department of Oncology and Radiotherapy, University Hospital of Split	114
Neva Purgar Levarda, Marin Prpić, Davor Kust, Petar Suton, Ivan Kruljac, Marin Gregov, Iva Mrčela, Ana Fröbe P27 - V50 – Predictive marker in radiotherapy induced hypothyroidism in head and neck cancer patients	116
Kristina Urch, Neva Purgar Levarda, Marijana Jazvić, Željko Soldić, Ana Fröbe P28 - Treatment with CDK 4/6 inhibitors in metastatic hormon receptor positive, HER-2 negative breast cancer – a single center experience	118
Neva Purgar Levarda, Kristina Urch, Jasna Radić, Jasmina Marić Brozić, Ana Fröbe P29 - Multidisciplinary team for thoracic tumors at University Hospital Center Sestre milosrdnice in 2019	119
Marija Pancirov, Ana Majić, Snježana Tomić, Krešimir Dolić, Mladen Krnić, Branka Petrić-Miše, Eduard Vrdoljak P30 - First experiences of alpelisib treatment of HR + HER2- metastatic breast carcinoma in Croatia	121
Jure Murgić, Tihomir Jurić, Matej Knežević, Boris Ružić, Ana Fröbe P31 - Prostate cancer treatment decision support tool for patients: development and translation of smart phone app to the clinic. Results of the prospective pilot study	123
Dora Franceschi, Antonela Vrljičak, Kristina Urch, Marijana Jazvić, Željko Soldić, Ana Fröbe P32 - Neoadjuvant therapy in breast cancer – a single center experience	125
Vladimir Ferenčak, Marjan Marić, Ahmad El Saleh, Željko Kaštelan P33 - Angiomyxoma testis: a rare case	126
Vladimir Ferenčak, Tomislav Kuliš, Ahmad El Saleh, Željko Kaštelan P34 - Multidisciplinary surgical approach to the treatment of renal cell cancer stage T3C	128
Angela Prgomet, Jure Murgić, Marijana Jazvić, Monika Ulamec, Marija Miletić, Ana Fröbe P35 - Early experience with neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from single institution retrospective evaluation	130

Dora Čerina, Andrija Katić, Ana Paparella Karaman, Darijo Hrepić, Eduard Vrdoljak P36 - Could ratio of untreated/treated patients with metastatic colorectal carcinoma indicate it`s quality of care?	132
Dora Čerina, Andrija Katić, Ana Paparella Karaman, Darijo Hrepić, Eduard Vrdoljak P37 - Molecular profiling frequency of metastatic colorectal carcinoma and it`s impact on the outcomes: a single institution status report in 2017	134
Kristina Urch, Dora Franceschi, Jasmina Marić Brozić, Nina Dabelić, Ana Fröbe P38 - Immunotherapy in treatment of metastatic melanoma at University Hospital Center Sestre milosrdnice	136
Damir Vučinić, Dag Zahirović, Ingrid Belac-Lovasić, Leo Kovač, Margira Belušić-Gobić, Blaženka Grahovac, Mirna Šitum, Gordana Zamolo P39 - Regulation of PD-1/PD-11 pathway in malignant melanoma – a pilot study	138
Dora Čerina, Marija Pancirov Jazvo, Darijo Hrepić, Eduard Vrdoljak P40 - Hepatotoxicity profiles of biosimilars vs. generic anti-her2 therapy in everyday clinical practice- observational study at the Department of Oncology and Radiotherapy, University Hospital of Split	140
Ana Car Peterko, Manuela Avirović, Iva Skočilić, Petra Valković Zujjić, Ingrid Belac Lovasić, Franjo Lovasić P41 - Institutional data on survival and disease control for early and locally advanced breast cancer patients in the era conservative surgical and adjuvant oncological approaches	142
AUTHOR INDEX	145